

ESMO Preceptorship on Breast Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**SINGAPORE
3-4 DECEMBER 2025**

CO-CHAIRS

Rebecca A. Dent, Singapore

Matteo Lambertini, Italy

esmo.org

ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
3-4 December 2025

CO-CHAIRS

Rebecca A. Dent, Singapore
Matteo Lambertini, Italy

SPEAKERS

Peter Dubsky, Switzerland	Icro Meattini, Italy
Hee Jeong Kim, Republic of Korea	Kevin Punie, Belgium
Sung-Bae Kim, Republic of Korea	Puay Hoon Tan, Singapore
Soo Chin Lee, Singapore	

LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care, management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by:



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 3 December 2025

09:00-09:10 10'	Opening and welcome	
10'	Welcome and introduction	Rebecca A. Dent, SG Matteo Lambertini, IT
09:10-10:45 95'	SESSION 1 HER2+ Breast Cancer	Chair: Rebecca A. Dent, SG
25'	Optimising (neo)adjuvant systemic therapy in HER2+ breast cancer: Where are we in escalation and de-escalation?	Sung-Bae Kim, KR
25'	Systemic therapy for HER2+ advanced breast cancer: Current state-of-the-art and future perspectives	Matteo Lambertini, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
10:45-11:15	Coffee break	
11:15-12:00 45'	SESSION 2 Pathology	Chair: Kevin Punie, BE
30'	Basics of pathology	Puay Hoon Tan, SG
15'	Q&A	All
12:00-12:55 55'	SESSION 3 Biology	Chair: Rebecca A. Dent, SG
25'	Applying the new breast cancer classification and new technologies (including NGS and ESCAT scale) in everyday practice	Kevin Punie, BE
20'	Use of genomic assays in early breast cancer	Kevin Punie, BE
10'	Q&A	All
12:55-13:55	Lunch	
13:55-15:20 85'	SESSION 4 Triple Negative Breast Cancer (TNBC)	Chair: Rebecca A. Dent, SG
20'	What is the optimal therapy in TNBC according to stage at diagnosis and pathological response?	Rebecca A. Dent, SG
20'	Systemic therapy for advanced TNBC	Rebecca A. Dent, SG
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
15:20-15:50	Coffee break	
15:50-17:30 100'	SESSION 5 Breast cancer om young women	Chair: Matteo Lambertini, IT
20'	Oncofertility care in young women with breast cancer	Matteo Lambertini, IT
20'	Optimising ovarian suppression including side effects management in pre-menopausal women with breast cancer	Hee Jeong Kim, KR
10'	Q&A	All
50'	Participants clinical case discussion (5x10')	Faculty
19:00	Networking dinner	

Thursday, 4 December 2025

09:00-10:05 65'	SESSION 6 Local-regional treatment	Chair: Icro Meattini, IT
25'	Surgery of the breast and the axilla: Where are we?	Peter Dubsy, CH
25'	Radiotherapy: How short is enough?	Icro Meattini, IT
15'	Q&A	All
10:05-11:00 55'	SESSION 7 Early ER+ Breast Cancer	Chair: Soo Chin Lee, SG
20'	Adjuvant initial and extended endocrine therapy in ER+ early breast cancer	Hee Jeong Kim, KR
20'	Best (neo-) adjuvant systemic therapy in high-risk ER+ HER2-breast cancer: Choice of chemotherapy and role of CDK4/6i	Icro Meattini, IT
15'	Q&A	All
11:00-11:30	Coffee break	
11:30-12:15 45'	SESSION 8 Issues in Advanced Breast Cancer	Chair: Rebecca A. Dent, SG
30'	ER+ advanced breast cancer: First line therapy and beyond (PIK3CA, ESR1 mutations, ADCs, AKT, etc)	Soo Chin Lee, SG
15'	Q&A	All
12:15-12:50 35'	SESSION 9 BRCA	Chair: Matteo Lambertini, IT
20'	Genetic counselling/testing and its therapeutic implications	Soo Chin Lee, SG
15'	Q&A	All
12:50-12:55 5'	Closing remarks	Rebecca A. Dent, SG Matteo Lambertini, IT
12:55-13:55	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion